Perforating dermatosis associated with multikinase inhibitors: report of two cases, including one associated with lenvatinib

Necrotic plaques in an elderly male

“…2,4 Acquired Reactive Perforating Collagenosis may be associated with use of immunotherapeutic agents including epidermal growth factor receptor inhibitors (tyrosine kinase-i) including Erlotinib, Sorafenib and Lenvatinib and use of Ranibizumab (anti-angiogenic monoclonal antibody used in wet age-related macular degeneration). 5,6 Dermatoscopic features Ormerod et al analysed some dermatoscopic features of reactive perforating collagenosis which included a hyperkeratotic plug appearing as yellow brown structureless areas surrounded by an erythematous rim of inflammation. 7 Figure 1.…”